<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00667888</url>
  </required_header>
  <id_info>
    <org_study_id>ID00-381</org_study_id>
    <secondary_id>NCI-2010-01456</secondary_id>
    <nct_id>NCT00667888</nct_id>
  </id_info>
  <brief_title>A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation</brief_title>
  <official_title>A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to compare using external beam radiotherapy with&#xD;
      intensity modulated beams for fewer days at a higher dose per day to the same type of therapy&#xD;
      for more days at a lower dose per day in the treatment of prostate cancer. The safety of&#xD;
      these treatments will also be studied and compared.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients in this study will be randomly picked (as in the toss of a coin) to be in one of two&#xD;
      treatment groups. There is an equal chance of being in either group.&#xD;
&#xD;
      Patients in Group 1 will be treated with intensity modulated radiotherapy (IMRT). These&#xD;
      patients will receive 42 treatments, 5 days per week, over 8.5 weeks. This method has become&#xD;
      the standard treatment at M.D. Anderson Cancer Center.&#xD;
&#xD;
      Patients in Group 2 will also be treated with IMRT. However, these patients will only receive&#xD;
      30 treatments, 5 days per week, over 6 weeks. The dose per day for Group 2 patients is higher&#xD;
      than for Group 1 and has the possibility of killing more tumor cells.&#xD;
&#xD;
      Each external beam treatment requires about 10-20 minutes. However, patients can expect to&#xD;
      spend 20 - 30 minutes on the treatment table because imaging measurements of prostate&#xD;
      position will be done before each treatment. The total time in the radiation department each&#xD;
      treatment day will be about an hour.&#xD;
&#xD;
      After the radiotherapy is completed, patients will have a PSA blood test every 3 months for 2&#xD;
      years, then every 6 months for Years 3 - 5, then annually. They will be examined every 6&#xD;
      months during the first 2 years beginning 3 months after the completion of treatment, then&#xD;
      annually. A needle biopsy of the prostate will be performed if these tests suggest&#xD;
      recurrence.&#xD;
&#xD;
      This is an investigational study. 225 patients will take part in this study. This study will&#xD;
      take place at M. D. Anderson and possibly some affiliated hospitals.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 3, 2001</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Actual">October 12, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Conventional Radiotherapy (CIMRT) Versus Hypofractionated Radiotherapy (HIMRT)</measure>
    <time_frame>8.5 years</time_frame>
    <description>To determine the progression of the number of participants who failed treatment after receiving (CIMRT) versus (HIMRT). PSA measured on (CIMRT) and (HIMRT) for each participant on both arms. Failure was defined as Prostate-specific antigen (PSA) failure using the Phoenix definition of nadir plus 2 ng/ml, or initiation of salvage therapy.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">225</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Intensity Modulated Radiotherapy (IMRT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A total dose of 75.6 Gy will be delivered in 42 fractions to the planning target volume (PTV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypofractionated Intensity Modulated Radiotherapy (HIMRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total dose of 72 Gy will be delivered in 30 fractions to the PTV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Conventional Fractionated Intensity Modulated Radiotherapy</intervention_name>
    <description>A total dose of 75.6 Gy will be delivered in 42 fractions to the planning target volume (PTV).</description>
    <arm_group_label>Intensity Modulated Radiotherapy (IMRT)</arm_group_label>
    <other_name>IMRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated Intensity Modulated Radiotherapy</intervention_name>
    <description>A total dose of 72 Gy will be delivered in 30 fractions to the PTV.</description>
    <arm_group_label>Hypofractionated Intensity Modulated Radiotherapy (HIMRT)</arm_group_label>
    <other_name>HIMRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Biopsy proof of adenocarcinoma of the prostate.&#xD;
&#xD;
          2. Bone scan (If PSA &gt;10 ng/ml or T3 disease) within 3 months of starting androgen&#xD;
             ablation or signing protocol consent if no androgen ablation.&#xD;
&#xD;
          3. CT-scan of pelvis (If Stage T3 disease) within 3 months of starting androgen ablation&#xD;
             or signing protocol consent if no androgen ablation.&#xD;
&#xD;
          4. Suitable medical condition; Zubrod &lt;2.&#xD;
&#xD;
          5. Pretreatment PSA &lt;/=20 ng/ml. If PSA &lt;4, must have Gleason greater than or equal to 7&#xD;
             and/or Stage T2b-T2c. PSA within 30 days of signing protocol consent. If neoadjuvant&#xD;
             androgen ablation has been given, then the preandrogen ablation PSA should be used for&#xD;
             stratification.&#xD;
&#xD;
          6. Clinical (palpable) Stage T1b - T3b disease (1992 AJCC staging system).&#xD;
&#xD;
          7. While a transrectal ultrasound will be obtained before treatment, the staging will not&#xD;
             be based on these findings. If palpable T3 disease is present, then must have Gleason&#xD;
             score &lt;8 and pretreatment PSA less than or equal to 10 ng/ml&#xD;
&#xD;
          8. Gleason score &lt;10.&#xD;
&#xD;
          9. If Gleason score 8 or 9, then must have stage T1/T2 disease and pretreatment PSA less&#xD;
             than or equal to 10 ng/ml.&#xD;
&#xD;
         10. The patient must be able to understand the protocol and adhere to follow-up at 6-month&#xD;
             intervals for the first 2 years and at yearly intervals thereafter.&#xD;
&#xD;
         11. Informed consent must be given.&#xD;
&#xD;
         12. Patients randomized to Arm 1 may also participate in protocol 2004-0428.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior pelvic radiotherapy.&#xD;
&#xD;
          2. Greater than 4 months of prior hormone ablation therapy.&#xD;
&#xD;
          3. Prior or planned radical prostate surgery.&#xD;
&#xD;
          4. Clinical, radiographic or pathologic evidence of nodal or distant metastatic disease.&#xD;
&#xD;
          5. Concurrent, active malignancy, other than nonmetastatic skin cancer or early stage&#xD;
             -chronic lymphocytic leukemia (well-differentiated small cell lymphocytic lymphoma).&#xD;
             If a prior malignancy is in remission for greater than or equal to 5 yr then the&#xD;
             patient is eligible.&#xD;
&#xD;
          6. Zubrod status greater than or equal to 2.&#xD;
&#xD;
          7. Pretreatment PSA &gt;20 ng/ml.&#xD;
&#xD;
          8. Gleason score of 10.&#xD;
&#xD;
          9. Palpable stage T3c (seminal vesicle involvement) or T4 disease.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah A. Kuban, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 24, 2008</study_first_submitted>
  <study_first_submitted_qc>April 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2008</study_first_posted>
  <results_first_submitted>January 4, 2021</results_first_submitted>
  <results_first_submitted_qc>January 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 25, 2021</results_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Radiation</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Intensity Modulated Radiotherapy</keyword>
  <keyword>IMRT</keyword>
  <keyword>Hypofractionated Intensity Modulated Radiotherapy</keyword>
  <keyword>HIMRT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients referred for radiotherapy with histologically proven adenocarcinoma of the prostate with clinical stage T1b-T3b disease and without clinical radiographic evidence of metastasis from 2001-2010.</recruitment_details>
      <pre_assignment_details>225 patient enrolled on the trial, 222 patients met criteria and participated to be randomized on trial. 203 patients were deemed evaluable.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: (CIMRT) Conventional Radiotherapy</title>
          <description>Patients' radiotherapy plan includes 75.6 Gy in 1.8-Gy fractions delivered over 8.4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: (HIMRT) Hypofractionated Radiotherapy</title>
          <description>Patients' radiotherapy plan includes 72 Gy in 2.4 Gy fractions delivered over 6 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Proceed with other treatment</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible after SIM</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1: (CIMRT) Conventional Radiotherapy</title>
          <description>Patients' radiotherapy plan includes 75.6 Gy in 1.8-Gy fractions delivered over 8.4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: (HIMRT) Hypofractionated Radiotherapy</title>
          <description>Patients' radiotherapy plan includes 72 Gy in 2.4 Gy fractions delivered over 6 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="111"/>
            <count group_id="B2" value="111"/>
            <count group_id="B3" value="222"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="204"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="178"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Conventional Radiotherapy (CIMRT) Versus Hypofractionated Radiotherapy (HIMRT)</title>
        <description>To determine the progression of the number of participants who failed treatment after receiving (CIMRT) versus (HIMRT). PSA measured on (CIMRT) and (HIMRT) for each participant on both arms. Failure was defined as Prostate-specific antigen (PSA) failure using the Phoenix definition of nadir plus 2 ng/ml, or initiation of salvage therapy.</description>
        <time_frame>8.5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: (CIMRT) Conventional Radiotherapy</title>
            <description>Patients' radiotherapy plan includes 75.6 Gy in 1.8-Gy fractions delivered over 8.4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: (HIMRT) Hypofractionated Radiotherapy</title>
            <description>Patients' radiotherapy plan includes 72 Gy in 2.4 Gy fractions delivered over 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Conventional Radiotherapy (CIMRT) Versus Hypofractionated Radiotherapy (HIMRT)</title>
          <description>To determine the progression of the number of participants who failed treatment after receiving (CIMRT) versus (HIMRT). PSA measured on (CIMRT) and (HIMRT) for each participant on both arms. Failure was defined as Prostate-specific antigen (PSA) failure using the Phoenix definition of nadir plus 2 ng/ml, or initiation of salvage therapy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8.5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm 1: (CIMRT) Conventional Radiotherapy</title>
          <description>Patients' radiotherapy plan includes 75.6 Gy in 1.8-Gy fractions delivered over 8.4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Arm 2: (HIMRT) Hypofractionated Radiotherapy</title>
          <description>Patients' radiotherapy plan includes 72 Gy in 2.4 Gy fractions delivered over 6 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Frequency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Urgency,Retention, Hesitancy/weak stream, Strictured</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Frequency</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Urgency,Retention, Hesitancy/weak stream, Strictured</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Karen Huffman, MD/ Associate Professor, Radiation Oncology Department</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>(713) 563-2339</phone>
      <email>khoffman1@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

